We evaluated the response and toxicity of Nedaplatin, a new platinum analog, in patients with recurrent and advanced esophageal carcinoma, and compared with Cisplatin. Material and Method: Seven patients with organ recurrence after curative esophagectomy and 21 with nonresected advanced esophageal carcinoma (18 squamous cell, 3 undifferentiated) were treated with 1 to 6 courses of Nedaplatin combined with 5-FU. Nedaplatin (100 mg/m2) was administered intravenously on day 1 followed by continuous infusion of 5-FU (500 mg/m2) from days 1 to 5. Result: Response was 29.2% in cases of squamous cell carcinoma. By disease site, response was 57.1% for the liver including 2 CR cases, 50% for the lung and kidney, and 55.5% for the lymph node. In cases of undifferentiated carcinoma, response was 66.6%. Grade 3 and 4 thrombocytopenia were observed in 14.8% and leukocytopenia in 7.4%. Nausea and vomiting were observed in 28.6%, and 1 case dropped out due to severe vomitting. No toxic effects were observed in 28.4% of all cases. Conclusion: Combined chemotherapy with Nedaplatin and 5-FU is useful in treating organ and lymph node metastasis in esophageal carcinoma, and is more effective than Cisplatin/5-FU combination therapy in lymph node metastasis. Toxicity was well tolerated.
- Esophageal carcinoma
ASJC Scopus subject areas